Item 16. Form 10-K Summary

5K characters. Original on sec.gov · Markdown

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


						AGILENT TECHNOLOGIES, INC.

						BY						/s/ MICHAEL TANG
												Michael Tang
												Senior Vice President,
												General Counsel and Secretary

Date: December 17, 2021

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Tang and P. Diana Chiu, or either of them, his or her attorneys-in-fact, for such person in any and all capacities, to sign any amendments to this report and to file the same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that any of said attorneys-in-fact, or substitute or substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.


Signature	Title	Date

/s/ MICHAEL R. MCMULLEN	Director, President and Chief Executive Officer	December 17, 2021
Michael R. McMullen	(Principal Executive Officer)

/s/ ROBERT W. MCMAHON	Senior Vice President and Chief Financial Officer	December 17, 2021
Robert W. McMahon	(Principal Financial Officer)

/s/ RODNEY GONSALVES	Vice President, Corporate Controllership	December 17, 2021
Rodney Gonsalves	(Principal Accounting Officer)

/s/ KOH BOON HWEE	Chairman of the Board of Directors	December 17, 2021
Koh Boon Hwee

/s/ MALA ANAND	Director	December 17, 2021
Mala Anand

/s/ HANS E. BISHOP	Director	December 17, 2021
Hans E. Bishop

/s/ OTIS W. BRAWLEY, M.D.	Director	December 17, 2021
Otis W. Brawley, M.D.

/s/ PAUL N. CLARK	Director	December 17, 2021
Paul N. Clark

/s/ G. MIKAEL DOLSTEN, M.D., PH.D.	Director	December 17, 2021
G. Mikael Dolsten, M.D., PH.D.

/s/ HEIDI KUNZ	Director	December 17, 2021
Heidi Kunz

/s/ DANIEL K. PODOLSKY, M.D.	Director	December 17, 2021
Daniel K. Podolsky, M.D.

/s/ SUE H. RATAJ	Director	December 17, 2021
Sue H. Rataj

/s/ GEORGE A. SCANGOS, Ph.D.	Director	December 17, 2021
George A. Scangos, Ph.D.

/s/ DOW R. WILSON	Director	December 17, 2021
Dow R. Wilson

Previous: Item 15. Exhibits and Financial Statement Schedules